Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2)
Public ClinicalTrials.gov record NCT05262270. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized, Placebo-Controlled Trial of Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an 8-week, double-blind, randomized placebo-controlled trial of the efficacy of a combination of extended-release naltrexone (XR-NTX) and extended-release buprenorphine (XR-BUP) compared to matched placebo injections (PBO-Inj) for the treatment of cocaine use disorder (CUD).
Study identification
- NCT ID
- NCT05262270
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 427 participants
Conditions and interventions
Conditions
Interventions
- Extended-Release Naltrexone Drug
- Extended Release Buprenorphine Drug
- Placebo (PLB) Injectable matched to XR-NTX Drug
- Placebo (PLB) Injectable matched to XR-BUP Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 18, 2023 (Actual)
- Primary completion
- Jun 27, 2025 (Actual)
- Completion
- Jul 21, 2025 (Actual)
- Last update posted
- Oct 21, 2025
2023 – 2025
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35209 | — |
| University of Arkansas for Medical Sciences | Little Rock | Arkansas | 72205 | — |
| UCLA Vine Street Clinic | Los Angeles | California | 90038 | — |
| Center on Substance Use and Health (CSUH) | San Francisco | California | 94102 | — |
| Cove Behavioral Health | Tampa | Florida | 33605 | — |
| University of Illinois at Chicago | Chicago | Illinois | 60608 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| Mountain Manor Treatment Center | Baltimore | Maryland | 21229 | — |
| Berman Center for Outcomes and Clinical Research at Hennepin Healthcare | Minneapolis | Minnesota | 55404 | — |
| Addictions Institute of Mount Sinai | New York | New York | 10029 | — |
| UTSW Medical Center, Center for Depression Research and Clinical Care | Dallas | Texas | 75247 | — |
| University of Texas Health San Antonio | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05262270, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 21, 2025 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05262270 live on ClinicalTrials.gov.